Bispecific antibodies in the treatment of multiple myeloma

Bispecific antibodies in the treatment of multiple myeloma - Nature

Bispecific antibodies are dual antigen targeting constructs that engage the T cells to plasma cells through various target antigens.

Bispecific Therapies | International Myeloma Foundation

Bispecific antibodies (also known as bispecifics, or BsAbs) are an immunotherapy (immune cell therapy) showing promising clinical trial results.

Bispecific Antibodies for the Treatment of Multiple Myeloma - PubMed

Numerous bispecific agents are in clinical development with some on the precipice of regulatory approval. While BCMA remains the principal ...

Bispecific Antibodies for Multiple Myeloma: Six Things Your Patients ...

In 2022, the drug teclistamab became the first bispecific antibody to be approved by the U.S. Food and Drug Administration (FDA) for the ...

Bispecific Antibodies in Multiple Myeloma: Opportunities to Enhance ...

Bispecific antibodies represent a new treatment option for patients with myeloma. These antibodies activate the patient's own T-cells to kill their tumour ...

Bispecific Antibody Use in Patients With Lymphoma and Multiple ...

The current FDA-approved BsAbs for patients with relapsed or refractory multiple myeloma (RRMM) after four or more prior lines of therapy are ...

Bispecific Antibodies for Myeloma Treatment

One of the newest classes of drugs in multiple myeloma is a group of therapies known as bispecific antibodies. They are a form of ...

Current use of bispecific antibodies to treat multiple myeloma

This article focuses on the current use of BsAb in MM, reviewing the pre-clinical and clinical studies that support data-driven clinical decisions.

Dr Chari on Currently Available Bispecific Antibodies in Multiple ...

The first 2 BCMA-targeted bispecific antibodies that were FDA approved for the treatment of patients with multiple myeloma were teclistamab ...

Bispecific Antibodies in Refractory Multiple Myeloma: Basics and ...

In particular, teclistamab, which targets BCMA, has been approved by the FDA for the treatment of relapsed myeloma after 4 lines of therapy.

Infections following bispecific antibodies in myeloma: a systematic ...

Bispecific antibodies, a novel immunotherapy with promising efficacy against multiple myeloma, form immune synapses between T-cell surface ...

Bispecific Antibody Therapy in Multiple Myeloma - YouTube

Shonali Midha, MD, discusses opportunities for utilizing bispecific antibodies in treating relapsed/refractory multiple myeloma.

Bispecific antibodies for the treatment of relapsed/refractory multiple ...

Teclistamab is a bispecific antibody that targets BCMA expressed on the surface of myeloma cells and CD3 on the surface of T cells. In the multicohort phase I/ ...

Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for ...

The first bispecific antibody (bsAb) for the treatment of relapsed/refractory multiple myeloma (RRMM), teclistamab, has been approved in 2022.

T Cell–Redirecting Bispecific Antibodies in Multiple Myeloma

T cell–redirecting bispecific antibodies (BsAb) induce significant responses in heavily pretreated multiple myeloma. BsAbs are currently administered in a ...

Bispecific Antibodies in the Treatment of Multiple Myeloma - BINASSS

Most of the bispecific antibodies in clinical development in myeloma are targeting B-cell maturation antigen, and other targets are GPRC5D, FCRH5, CD38, and ...

Bispecific Antibodies in Multiple Myeloma | Dana-Farber ... - YouTube

Omar Nadeem, MD, explains bispecific antibodies as an exciting new immunotherapy treatment option for patients with relapsed or refractory ...

Bispecific Antibodies for Relapsed/Refractory Multiple Myeloma

It's a bispecific antibody where one of the effectors is binding to CD3, which is on T cells, and the other effector is binding to BCMA, which ...

Bispecific Antibodies in the Treatment of Multiple Myeloma

Bispecific antibodies (T-cell engaging antibodies) provide a new mode of action for anti-myeloma therapy by redirecting autologous T cells toward myeloma cells.

Bispecific antibodies in multiple myeloma treatment - Frontiers

Here, we summarize and highlight various bispecific immunotherapies under development in MM treatment, as well as the utility of combining them with current ...